Open-label, Multicenter, Interventional, Dose Titration Study to Assess the Long-term Study of CS-3150 2.5mg and 5mg Alone as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension
Phase of Trial: Phase III
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Esaxerenone (Primary)
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 10 Aug 2017 Status changed from active, no longer recruiting to completed.
- 14 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 01 Apr 2016 New trial record